Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study

We report the final 2-year end-of-study results from the first clinical trial investigating combination treatment with ruxolitinib and low-dose pegylated interferon-α2 (PEG-IFNα2). The study included 32 patients with polycythemia vera and 18 with primary or secondary myelofibrosis; 46 patients were...

Descrición completa

Detalles Bibliográficos

Principais autores:	Anders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen, Mads Emil Bjørn, Christen Lykkegaard Andersen, Ole Weis Bjerrum, Nana Brochmann, Dustin Andersen Patel, Lise Mette Rahbek Gjerdrum, Daniel El Fassi, Torben A. Kruse, Thomas Stauffer Larsen, Hans Torben Mourits-Andersen, Claus Henrik Nielsen, Christina Ellervik, Niels Pallisgaard, Mads Thomassen, Lasse Kjær, Vibe Skov, Hans Carl Hasselbalch
Formato:	Artigo
Idioma:	Inglês
Publicado:	Ferrata Storti Foundation 2020-01-01
Series:	Haematologica
Acceso en liña:	https://haematologica.org/article/view/9851
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!